← Back to Search

Procedure

Multiplexing Prism for Monocular Vision

N/A
Waitlist Available
Led By Jaehyun Jung, Ph.D.
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No medical health issues such as seizures, motor movements problem
Loss of vision in one eye (no light perception/enucleation/evisceration) for >1 year
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 sessions, up to 3 hours for each session, any time within 2 month period
Awards & highlights
No Placebo-Only Group

Summary

This trial is developing a device called a multiplexing prism that helps people who have lost one eye to see a wider field of view. They are testing a simpler design and way of fitting the device

Who is the study for?
This trial is for people who have lost vision in one eye for more than a year, but still have good vision (better than 20/32) in their other eye without any field defects. They should not have health issues like seizures or motor movement problems.
What is being tested?
The study is testing a device called a multiplexing prism designed to widen the visual field for those with sight in only one eye. The focus is on evaluating a new simplified design and how easy it is to fit this device to help with vision.
What are the potential side effects?
Since this trial involves an assistive device rather than medication, traditional side effects are not applicable. However, there may be discomfort or adjustment challenges when using the multiplexing prism.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I do not have seizures or problems with motor movements.
Select...
I have been blind in one eye for more than a year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 sessions, up to 3 hours for each session, any time within 2 month period
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 sessions, up to 3 hours for each session, any time within 2 month period for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Field expansion from multiplexing prism
Secondary study objectives
Maximum extent of nasal visual field with multiplexing prism

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Field ExpansionExperimental Treatment1 Intervention
Field of view on the nasal side (same side as the blind eye) with and without multiplexing prism

Find a Location

Who is running the clinical trial?

National Eye Institute (NEI)NIH
558 Previous Clinical Trials
1,408,461 Total Patients Enrolled
Massachusetts Eye and Ear InfirmaryLead Sponsor
111 Previous Clinical Trials
12,849 Total Patients Enrolled
Jaehyun Jung, Ph.D.Principal InvestigatorSchepens Eye Research Institute
Eli Peli, ODPrincipal InvestigatorSchepens Eye Research Institute
1 Previous Clinical Trials
10 Total Patients Enrolled
~5 spots leftby Dec 2025